How Master Protocol Trials Could Accelerate Rare Disease Research

One in 10 people faces a rare condition, yet approved medications treat just 4% of all diagnosed neurological disorders according to a publication released October 5, 2026, in the journal Annals of Neurology. Researchers from seven institutions detailed how master protocol trials could reshape rare disease research by evaluating multiple therapies or conditions within a shared clinical framework.

Shared Clinical Frameworks Lower Research Costs

Traditional clinical trials require building a brand-new framework for every single drug or condition tested. Master protocol trials change that approach by testing multiple therapies or conditions at the same time using a single infrastructure. This shared structure can improve testing efficiency and speed up treatments for patients who currently have no options.

According to the report from Dr. Erika Augustine, the study’s senior author as well as associate chief science officer and director of the Clinical Trials Unit at Kennedy Krieger Institute, households affected by rare neurological conditions lack the luxury of waiting for research to advance at conventional speeds.

Master protocol trials offer a smarter, more collaborative way to evaluate potential therapies and bring effective treatments to patients more efficiently, Dr. Augustine stated.

Genetic Overlaps Drive Collaborative Trial Design

Rare disease researchers recently discovered that similar genetic markers appear across multiple conditions. That biological overlap, combined with advances in targeted gene therapies, provides a clear rationale for evaluating treatments across several conditions simultaneously.

The study notes that the United States defines a rare disease as any condition affecting fewer than 200,000 people. Despite that low threshold for individual conditions, rare diseases as a group are common because 10% of the population receives a rare diagnosis. More than 10,000 rare diseases exist, with the majority involving neurological symptoms that range from developmental disabilities to problems with body control.

The U.S. Food and Drug Administration approved 45 drug therapy options for neurological conditions, which treat only 26 different conditions.

Specialists hailing from Kennedy Krieger Institute; University of Rochester Medicine; Berry Consultants; Mass General Brigham, Spaulding Rehabilitation, and Harvard Medical School; the Clinical Trials Transformation Initiative at Duke University; Rady Children’s Health and UC Irvine; and the Batten Disease Support, Research, and Advocacy Foundation joined forces to write the joint publication.

Working together, rather than in isolation, can help us answer important questions more efficiently and accelerate progress for patients and families.

Dr. Jennifer Vermilion, University of Rochester Batten Center of Excellence

The Kennedy Krieger Institute notes that basket, umbrella, and platform trials represent the primary structural examples of master protocol designs.